65,437 trials
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 6.1 percentage of participants
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.5; -4.8; -4.9; -3.4 units on a scale
Acute Myocardial Infarction
Primary: Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention — 100; 100 Percent diameter…
Infertility
Primary: Number of Oocytes Retrieved Per Participant — 10.0; 11.8 oocytes — p=0.037
Rhinoconjunctivitis · Rhinitis · Conjunctivitis
Primary: Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS) — 5.08; 6.39 Units on a Scale — p==0.005
Neuroendocrine Tumor · Islet Cell Tumor
Primary: Percentage of Participants With Progression Free Survival (PFS) at 12 Months — 66 percentage of participants
Epilepsy
Primary: Change in the Number of Seizure Days With Absence Seizures From the Baseline Phase to the Maintenance Phase — -0.37 number of seizure days
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.5; -4.5; -4.6; -3.0 units on a scale
Endocarditis
Primary: Number of Participants With In-hospital Death or Clinical Embolic Events — 9; 1 participants — p=<0.05
Rhinoconjunctivitis · Rhinitis · Conjunctivitis
Primary: Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS) — 4.62; 6.25 Units on a Scale — p==0.001
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Change in Hair Count at 16 and 26 Weeks Over Baseline — -0.8; 12.5; 3.0; 20.6 hairs per cm^2
Renal Cell Carcinoma
Primary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline
Brain and Central Nervous System Tumors · Chronic Myeloproliferative Disorders · Leukemia
Primary: Pain Intensity — 5.60; 6.44; 5.11; 5.98 units on a scale
Low Back Pain
Primary: Change in FFbH-R Between Screening and Week 15 — 8.8; 4.1 units on a scale — p=0.0426
Breast Cancer
Primary: Best Overall Response Rate (BORR) (Calliper) — 70.4; 50.5 Percentage of Participants